The polycyclic, xanthone antibiotic IB-00208 (**1**) (Figure [1](#fig1){ref-type="fig"}) was isolated by Romero and co-workers in 2003 from the culture broth of *Actinomadura* sp.^[@ref1]^ This novel compound exhibits potent cytotoxic activity (MIC = 1 nM) against several tumor cell lines including P388D1, A-549, HT-29, and SK-MEL-28, as well as strong antibiotic activity against several Gram-positive bacteria. The hexacyclic core of IB-00208 contains a 1,4-dioxygenated xanthone subunit and is structurally related to citreamicin α (**2**),^[@ref2]^ kibdelone A (**3**),^[@ref3]^ and cervinomycin A~2~ (**4**),^[@ref4]^ all of which exhibit significant biological activities (Figure [1](#fig1){ref-type="fig"}). The relative stereochemistry of the sugar moiety in IB-00208 (**1**) was established by analysis of spin--spin coupling constants and supported by NOESY experiments; however, the absolute stereochemistry at C(3) of **1** is not known.
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Owing to the complex polycyclic structures and potent biological activities of **1**--**4**, there has been considerable interest in the total synthesis of these and other polycyclic xanthones,^[@ref5]−[@ref7]^ but neither IB-00208 nor citreamicin α has yet succumbed to total synthesis. A key structural subunit embedded in many of these natural products is a 1,4-dioxygenated xanthone, which itself presents significant challenges to synthesis.^[@ref8]^ In the context of our interest in these and other polycyclic xanthone natural products, we recently developed a concise route to 1,4-dioxygenated xanthones that features a novel extension of the Moore cyclization,^[@ref9],[@ref10]^ and we now report the application of this general entry to xanthones to the first total synthesis of the aglycone of IB-00208.

Our approach to IB-00208 (**1**) is outlined in a retrosynthetic format in Scheme [1](#sch1){ref-type="scheme"}. We reasoned that the late stage intermediate **5** could be converted into **1** via benzylic oxidation, quinone formation, deprotection, and stereo- and regioselective glycosylation of the sterically less encumbered phenolic group. In our original plan, we had envisioned that electrocyclic ring opening of **7** would generate the acetylenic vinyl ketene **6** in accord with the findings of Moore.^[@ref9]^ Simple analogs of **6** can cyclize via a radical pathway, a reaction manifold that our group leveraged in a concise total synthesis of cribrostatin 6,^[@ref11]^ but compound **6** is also suitably substituted to undergo cyclization via an ionic pathway to give **5** in a process inspired by a related transformation reported by Fuganti.^[@ref12]^ Intermediate **7** would be accessed by union of the aldehyde **8** and the key intermediate fused-cyclobutenone **9** by an acetylide stitching sequence. When we initiated this project, angular, polycyclic cyclobutenedione derivatives such as **9** were unknown, but we reasoned **9** might be accessible from coupling of **10** and the known vinyl squarate **11**,^[@ref13]^ followed by ring closing metathesis (RCM) to form the benzene ring in **9**.
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Toward preparing the fused cyclobutenedione **9**, commercially available 2-bromo-1,4-dimethoxybenzene (**12**) was treated with *n*-BuLi, and the resulting aryllithium reagent was allowed to react with propylene oxide to yield the racemic secondary alcohol **13** (Scheme [2](#sch2){ref-type="scheme"}).^[@ref14]^ Although the absolute stereochemistry at C(3) of **1** is unknown, both enantiomers of propylene oxide are commercially available, so it is possible to prepare either enantiomer of **13**, and hence of the aglycone of **1**, via this approach. Regioselective bromination of **13** by NBS in the presence of a catalytic amount of ammonium nitrate (NH~4~NO~3~),^[@ref15]^ followed by installation of a MOM group, which served the dual roles of being a protecting group and the source of a carbon atom in the A-ring, gave **14** in excellent yield. The hydroquinone protecting groups were easily removed by a redox process, and a TMSOTf-induced oxa-Pictet--Spengler cyclization generated the dihydropyran ring of **15**.^[@ref16]^ A Duff reaction of **15** with hexamethylenetetramine (HMTA)^[@ref17]^ gave **16** in 58% overall yield from **14**. Protection of the hydroquinone moiety in **16** as its bis-MOM ether, followed by Wittig olefination, furnished **10** in 73% overall yield. The aryllithium reagent derived from **10** by metal--halogen exchange was then coupled with vinyl squarate **11** following a procedure reported by Moore^[@ref13]^ to give **18** in 64% yield.^[@ref18]^ RCM of **18** in the presence of Grubbs II catalyst afforded cyclobutenone **9** in 81% yield.
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The next stage of the synthesis involved an acetylide stitching process to assemble a compound related to **7**. Accordingly, **9** was converted into propargyl alcohol **19** in 88% yield (Scheme [3](#sch3){ref-type="scheme"}). Double deprotonation of **19** using an excess of the strong, non-nucleophilic base bromomagnesium 2,2,6,6-tetramethylpiperidide (TMPMgBr) generated a dianion that was coupled with aldehyde **8**, which was prepared via silylation^[@ref19]^ of the corresponding known phenol,^[@ref20]^ to deliver **20** in 80% yield.

![Preparation of **20** by Acetylide Stitching](ol-2014-03336t_0005){#sch3}

At this juncture, the key sequence of electrocyclic ring opening and subsequent cyclizations was at hand. In model studies with an analog of **20** lacking the A-ring, we were unable to selectively oxidize the acetylenic-benzylic alcohol moiety to give a ketone. In view of this unfavorable precedent, the ketal group in **20** was removed to deliver **21** (Scheme [4](#sch4){ref-type="scheme"}), which upon heating in DMSO (0.005 M) at 100 °C gave **22** in 54% overall yield from **20**. No hexacyclic product related to **5** that would have arisen from cyclization of a putative acetylenic vinyl ketene as expected from the work of Fuganti^[@ref12]^ was observed under any of the conditions examined. Rather, **21** simply underwent a Moore rearrangement to give exclusively benzoquinone **22**.^[@ref9],[@ref10]^

![Sequential Rearrangement and Cyclizations of **21**](ol-2014-03336t_0006){#sch4}

Completing the synthesis of IB-00208 (**1**) from **22** required selective oxidations of the secondary alcohol at C(15) and the methylene group at C(1) as well as cyclization to form the pyranone E-ring. In the event, benzylic oxidation at C(1) of **22** proceeded selectively with DDQ in the presence of MeOH^[@ref21]^ to produce the acetal **23** in 85% yield (Scheme [4](#sch4){ref-type="scheme"}). Oxidation of the alcohol at C(15) using IBX gave **24**, and subsequent fluoride-ion induced removal of the TBS group gave spirocycle **25** via spontaneous cyclization of the intermediate phenoxide. The regiochemical outcome of this cyclization to form a spirocyclic ring system rather than the desired 1,4-dioxygenated xanthone is consistent with previous observations from our laboratory that the substitution pattern on the F-ring of **24** governs the regioselectivity.^[@ref10]^ Hydrolysis of the C(1) acetal followed by oxidation of the intermediate hemiacetal with pyridinium dichromate (PDC) in the presence of 3 Å molecular sieves gave lactone **26** in 81% overall yield from **25**.^[@ref22]^

We have shown that simpler spirocyclic ketones related to **26** undergo rearrangement to give xanthones,^[@ref10]^ so we were gratified to discover that heating **26** at 180 °C in a microwave reactor gave a mixture of hydroquinone **27** and quinone **28**, both of which lacked the phenolic MOM protecting group at C(17) (Scheme [5](#sch5){ref-type="scheme"}). Although oxidation of **27** to **28** occurred slowly upon exposure of **27** to air under ambient conditions, continued heating of a mixture of **27** and **28** in the presence of oxygen led to the exclusive formation of **28** in 79% yield from **26**. Initial attempts to remove the C(5) phenolic MOM protecting group of **28** under acidic conditions gave complex mixtures. However, reaction of **28** with freshly distilled TMSBr,^[@ref23]^ followed by workup and partial purification by fractional precipitation, furnished a mixture (∼2:1) of compounds for which the LC-HRMS and ^1^H NMR spectral data (see [Supporting Information](#notes-1){ref-type="notes"}) are consistent with those expected for **29a**, the aglycone of **1**, and its isomer **29b**, which is produced by tautomerization of the initially formed **29a**. It was perhaps not unexpected that the hydroquinone--quinone tautomers **29a** and **29b** were obtained upon deprotection of **28**, because the redox potentials of the B- and D-rings would be predicted to be similar, so **29a** and **29b** should be of comparable stability. Unfortunately, the tautomers **29a** and **29b** were somewhat prone to decomposition, so we were not able to separate or purify either of them for further characterization and elaboration.

![Synthesis of the Aglycone of IB-00208 (**1**)](ol-2014-03336t_0007){#sch5}

In summary, we completed the first total synthesis of racemic **29a**, the aglycone of IB-00208 (**1**), together with its hydroquinone--quinone tautomer **29b**. The longest linear sequence in the synthesis required 22 steps from commercially available starting materials. Preparation of key intermediate **9** via an RCM reaction represented a potentially general route to polycyclic benzocyclobutenedione derivatives, and an acetylide stitching process was exploited to couple **9** with an aryl aldehyde leading to ketone **21**. Our initial plan to form the hexacyclic framework of IB-00208 by a one-pot, electrocyclic ring-opening/cyclization cascade from **21** could not be implemented, but an alternative approach was adopted successfully that led to **28**, the monoprotected aglycone of IB-00208. Deprotection of **28** gave a mixture of the tautomeric aglycones **29a** and **29b**.

Complete experimental procedures, full characterization of new compounds, and copies of ^1^H and ^13^C NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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